Post-earnings, JNJ shares moved slightly, ending 0.5% lower at $154 on Tuesday, April 15th. Despite a broader market decline linked to tariffs, the stock is still up 7% year-to-date.

Yet JNJ ’s scale (it has a $369 billion market cap) and pipeline of 10 drugs targeting $5 billion in peak sales, mitigate them. In a tariff-rattled market, ...

Johnson & Johnson Beats And Raises, Shares Steady Johnson & Johnson had a great first quarter despite the impact of its COVID-19 vaccine getting sidelined. The company reported $22.32 billion in ...

Johnson & Johnson JNJ announced sales and earnings growth expectations for 2024 and the 2025-2030 period. ... the AI industry is predicted to have an internet and iPhone-scale economic impact of ...